(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 20.68% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Adma Biologics's revenue in 2024 is $283,176,466.On average, 2 Wall Street analysts forecast ADMA's revenue for 2024 to be $83,279,772,114, with the lowest ADMA revenue forecast at $82,964,511,606, and the highest ADMA revenue forecast at $83,595,032,622. On average, 2 Wall Street analysts forecast ADMA's revenue for 2025 to be $104,616,649,652, with the lowest ADMA revenue forecast at $95,322,259,898, and the highest ADMA revenue forecast at $113,911,039,406.
In 2026, ADMA is forecast to generate $111,152,509,962 in revenue, with the lowest revenue forecast at $111,152,509,962 and the highest revenue forecast at $111,152,509,962.